300 related articles for article (PubMed ID: 29682444)
1. Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice.
Milano A; Mazzetta F; Valente S; Ranieri D; Leone L; Botticelli A; Onesti CE; Lauro S; Raffa S; Torrisi MR; Marchetti P
Anal Cell Pathol (Amst); 2018; 2018():3506874. PubMed ID: 29682444
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
[TBL] [Abstract][Full Text] [Related]
4. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
Liu DG; Xue L; Li J; Yang Q; Peng JZ
Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
[TBL] [Abstract][Full Text] [Related]
6. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
8. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
[TBL] [Abstract][Full Text] [Related]
11. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells.
Li L; Yan S; Zhang H; Zhang M; Huang G; Chen M
BMC Cancer; 2019 Sep; 19(1):894. PubMed ID: 31492158
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
[TBL] [Abstract][Full Text] [Related]
14. Epithelial‑mesenchymal transition phenotype of circulating tumor cells is associated with distant metastasis in patients with NSCLC.
Zhang X; Wei L; Li J; Zheng J; Zhang S; Zhou J
Mol Med Rep; 2019 Jan; 19(1):601-608. PubMed ID: 30483792
[TBL] [Abstract][Full Text] [Related]
15. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
Morrow CJ; Trapani F; Metcalf RL; Bertolini G; Hodgkinson CL; Khandelwal G; Kelly P; Galvin M; Carter L; Simpson KL; Williamson S; Wirth C; Simms N; Frankliln L; Frese KK; Rothwell DG; Nonaka D; Miller CJ; Brady G; Blackhall FH; Dive C
Ann Oncol; 2016 Jun; 27(6):1155-1160. PubMed ID: 27013395
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
18. Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
Zhang Y; Men Y; Wang J; Xing P; Zhao J; Li J; Xu D; Hui Z; Cui W
J Cancer Res Clin Oncol; 2022 May; 148(5):1137-1146. PubMed ID: 34255149
[TBL] [Abstract][Full Text] [Related]
19. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.
He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP
J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
Rieckmann LM; Spohn M; Ruff L; Agorku D; Becker L; Borchers A; Krause J; O'Reilly R; Hille J; Velthaus-Rusik JL; Beumer N; Günther A; Willnow L; Imbusch CD; Iglauer P; Simon R; Franzenburg S; Winter H; Thomas M; Bokemeyer C; Gagliani N; Krebs CF; Sprick M; Hardt O; Riethdorf S; Trumpp A; Stoecklein NH; Peine S; Rosenstiel P; Pantel K; Loges S; Janning M
Mol Cancer; 2024 May; 23(1):93. PubMed ID: 38720314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
